MétaCan
Menu
Back to cohort
Record W2072331709 · doi:10.1158/1538-7445.am2012-3851

Abstract 3851: Killing of Kras mutant colon cancer cells by the αGBP cytokine, a physiological PI3K inhibitor therapeutically effective <i>in vivo</i>

2012· article· en· W2072331709 on OpenAlexaboutno aff
Livio Mallucci, Lavinia Vittoria Lotti, Renato Mariani‐Costantini, Valerie Wells, Daniel Zicha

Bibliographic record

VenueCancer Research · 2012
Typearticle
Languageen
FieldPharmacology, Toxicology and Pharmaceutics
TopicBioactive Compounds and Antitumor Agents
Canadian institutionsnot available
Fundersnot available
KeywordsKRASCancer researchPI3K/AKT/mTOR pathwayBiologyCancerCarcinogenesisColorectal cancerSignal transductionCell biology

Abstract

fetched live from OpenAlex

Abstract Activating Kras mutations are the most frequent oncogenic mutations in human cancer. Numerous downstream pathways responsible for cell proliferation and cell survival have been shown to be deregulated by oncogenic Kras but there are no effective targeted therapies to date for Kras driven oncogenesis. Mutant-activated Kras defines a subset of patients for whom prognosis is poor and therapeutic options are limited. We demonstrate that αGBP, a cytokine produced by CD4+ and CD8+ activated T cells, which operates by inhibiting class IA and class IB PI3K, is a potent activator of apoptosis in Kras-mutant colorectal cancer cells, even when co-harboring mutant-activated PIK3CA. Mechanics initiate with inhibition of PI3K activity and Rac-independent actin reorganisation assignable to phosphoinositide changes at the plasma membrane. Cyclin E deregulation, arrest of DNA synthesis and Chk2 activation underscore events critical to the activation of intrinsic apoptosis. Clustering of CD95/Fas death receptors underscores events critical to the activation of extrinsic apoptosis. In nude mice we present the first evidence that tumor development is strongly inhibited. This first demonstration of therapeutic efficacy against Kras-mutant colon cancer suggests that Hu-r-αGBP may be therapeutically effective against other cancers harbouring activating Ras mutations. Wells, V. and Mallucci, L. (2009). Phosphoinositide 3-kinase targeting by the β-galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death. Breast Cancer Research 11, R2, 1-10. Wells, V., Downward, D. and Mallucci, L. (2007). Functional inhibition of PI3K by the αGBP molecule suppresses Ras-MAPK signalling to block cell proliferation. Oncogene 26, 7709-7714. Mallucci, L. and Wells, V. (2007). Alternative use of signaling by the αGBP cytokine in cell growth modulation and cancer control. From surveillance to therapy. In: Apoptosis, Cell Signaling and Human Diseases. Ed. R. Srivastava. The Humana Press Inc. Vol. I, 203-216. Patents US patent no. 7,994,113 granted August 9th 2011 PCT WO 2008/152392: Europe, Canada, Australia, Japan, published Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3851. doi:1538-7445.AM2012-3851

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.061
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.002
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.204
GPT teacher head0.505
Teacher spread0.301 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2012
Admission routes1
Has abstractyes

Explore more

Same venueCancer ResearchSame topicBioactive Compounds and Antitumor AgentsFrench-language works237,207